top of page

IntraBio Media Release | February 7, 2024

Updated: Feb 9

The New England Journal of Medicine has published the detailed results of the IB1001-301 Phase 3, Pivotal study with N-acetyl-L-leucine (IB1001) for the treatment of NPC


Read the full announcement from IntraBio here:

Statement NEJM 4B1
.docx
Download DOCX • 15KB

Bremova-Ertl et al. 2024 NEJM
.pdf
Download PDF • 694KB

The New England Journal of Medicine (NEJM) has published the detailed results of the IB1001-301 Phase 3, Pivotal study with N-acetyl-L-leucine (IB1001) for the treatment of Niemann-Pick disease Type C (NPC): https://www.nejm.org/doi/full/10.1056/NEJMoa2310151 (note - the article/ quick take video, are available to download / view for free if you register an account).

 

To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."


Ways to support NP-C in Australia:

39 views0 comments

Recent Posts

See All

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page